Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘AACR’

AACR Advances in Prostate Cancer Research Meeting

By on January 31, 2012

A scientific meeting that I would have liked to have attended and one where I think attendees will obtain a lot of insight into the future of prostate cancer research is the forthcoming American Association for Cancer Research (AACR) Advances in Prostate Cancer Research meeting.

AACR Advances in Prostate Cancer Banner AACR Advances in Prostate Cancer Research MeetingChaired by Charles Sawyers (MSKCC) and Arul Chinnayan (Michigan) it has an impressive line-up of speakers and sessions.  The meeting takes place next week (Feb 6-9) in Orlando.

There are two presentations on cabozantib (XL184) that may offer new insights into the mechanism of action of the drug and its potential:

This is a preview of AACR Advances in Prostate Cancer Research Meeting. Read the full post

1 Comment

Update from AACR on new prostate cancer drugs to watch

By on April 7, 2011

AACR 2011 Annual Meeting Banner 300x225 Update from AACR on new prostate cancer drugs to watchThe 102nd Annual meeting of the American Association for Cancer Research (AACR) ended yesterday in Orlando, and it was only the diehards who kept going till the last session of the last day for an update on “Novel Androgen Receptor Antagonists.”

As I mentioned in an earlier post, there is a lot of excitement in the prostate cancer field at the moment with three new therapies approved last year (cabazitaxel, sipuleucel-T, denosumab), and more expected over the next two years (abiraterone acetate, MDV3100, cabozantinib/XL-184).

This is a preview of Update from AACR on new prostate cancer drugs to watch. Read the full post

Leave a comment

AACR 2011: My Poster of the Day

By on April 4, 2011

Faced with the opportunity to read around 900+ posters yesterday afternoon in the first of the six main poster sessions from Sunday to Wednesday here at the AACR annual meeting, any selection of a “poster of the day” is extremely subjective.  All the posters here have considerable scientific merit having passed a rigorous peer-review selection process.

Faced with a smorgasboard of choice, one ends up focusing on areas of personal interest. One area I have recently started to write about on this blog is the impact nanotechnology may have on cancer research and in particular how nanoparticles in the form of diamonds can be used to reach into tumors.

This is a preview of AACR 2011: My Poster of the Day. Read the full post

Leave a comment

AACR 2011 posters: a window into the world of emerging science

By on April 3, 2011

AACR 2011 Bag 150x150 AACR 2011 posters: a window into the world of emerging scienceThere are 5,396 posters at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) here in Orlando. Intermingled with the exhibitors (something that no doubt encourages traffic to the exhibits), the posters provide a window into the world of current cancer research and the spirit of collaboration.

Researchers from all over the world present their latest scientific discoveries, what they may have spent 3 years or more years on while studying for a Ph.D or undertaking a post-doctoral fellowship.

The research is innovative, and what’s seen at AACR is often at the cutting edge and shown prior to publication in a major journal.

This is a preview of AACR 2011 posters: a window into the world of emerging science. Read the full post

Leave a comment

Cancer Discovery – an exciting new journal launched by AACR

By on April 3, 2011

AACR Cancer Discovery April 2011 224x300 Cancer Discovery an exciting new journal launched by AACRIt’s a busy day of science at the 102nd American Association for Cancer Research (AACR) annual meeting in Orlando, You can follow what’s happening on twitter, #AACR.  Pharma Strategy Blog has an excellent “Cover it Live” widget that shows everyone’s #AACR tweets. It allows you to go back in time, so you can see what happened earlier.  AACR also has some excellent webcasts and podcasts from the meeting.

However, what caught my attention this morning was the launch of a new journal, Cancer Discovery; preview copies were handed out to attendees at the plenary session this morning.

This is a preview of Cancer Discovery – an exciting new journal launched by AACR. Read the full post

Leave a comment

Gilead acquires Calistoga and CAL-101 for $375M

By on February 22, 2011

Gilead Sciences Logo 300x120 Gilead acquires Calistoga and CAL 101 for $375M

In an acquisition that highlights the importance of cancer and inflammation, Gilead Sciences today announced the acquisition of Seattle based Calistoga Pharmaceuticals for $375M.

Calistoga’s pipeline is focused on the development of PI3 kinase inhibitors for cancer and inflammation. Sally Church on Pharma Strategy Blog has written extensively about “The potential of the PI3K pathway inhibitors in lung cancer”, and discussed Calistoga’s CAL-101 compound and its development for hematological malignancies in her report on “What’s hot at ASH in 2010”.

This is a preview of Gilead acquires Calistoga and CAL-101 for $375M. Read the full post

1 Comment